[Cerebrolysin treatment of mild cognitive impairment of vascular genesis].
OBJECTIVE
To evaluate effects of cerebrolysin on cognitive functions in patients with mild cognitive impairment of vascular genesis.


METHODS
The examination covered 43 patients aged 40 to 80 years with mild cognitive impairment. We used Tinetti scale for assessment of dynamics in postural disorders; neuropsychological examination was based on Short Scale of Psychic Status Assessment, Mattis Dementia Scale, ADAS- Cog scale, digit test and other tests. Cerebrolysin was injected in drops intravenously in a dose 10 ml per 200 ml of the physiological solution. The course included 20 injections with immediate assessment of the response and 3 months after the course.


RESULTS
Cerebrolysin improved motor activity, memory, attention, general cognitive status. The effect is delayed and was noticeable 3 months after the end of the treatment course. Side effects were absent.


CONCLUSIONS
Cerebrolysin influences neurodynamic aspects of mnestic and cognitive activity associated with frontal-subcortical relations that also results in motor activity improvement.
I V
IV
Damulin
E A
EA
Mkhitarian
N N
NN
Koberskaia
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000596:Amino Acids / Q000008:administration & dosage*; D001921:Brain; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014715:Vertebrobasilar Insufficiency / Q000150:complications* / Q000188:drug therapy
D000596:Amino Acids; D018696:Neuroprotective Agents; C006952:cerebrolysin